These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35236367)

  • 1. Addressing the need for patient-friendly medical communications: adaptation of the 2019 recommendations for the management of MPS VI and MPS IVA.
    Bruce IA; Ezgü FS; Kampmann C; Kenis V; Mackenzie W; Stevens B; Walker R; Hendriksz C
    Orphanet J Rare Dis; 2022 Mar; 17(1):91. PubMed ID: 35236367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.
    Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
    Orphanet J Rare Dis; 2019 Jun; 14(1):137. PubMed ID: 31196221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucopolysaccharidosis IVA (Morquio A syndrome) and VI (Maroteaux-Lamy syndrome): under-recognized and challenging to diagnose.
    Lachman RS; Burton BK; Clarke LA; Hoffinger S; Ikegawa S; Jin DK; Kano H; Kim OH; Lampe C; Mendelsohn NJ; Shediac R; Tanpaiboon P; White KK
    Skeletal Radiol; 2014 Mar; 43(3):359-69. PubMed ID: 24389823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations for the management of MPS VI: systematic evidence- and consensus-based guidance.
    Akyol MU; Alden TD; Amartino H; Ashworth J; Belani K; Berger KI; Borgo A; Braunlin E; Eto Y; Gold JI; Jester A; Jones SA; Karsli C; Mackenzie W; Marinho DR; McFadyen A; McGill J; Mitchell JJ; Muenzer J; Okuyama T; Orchard PJ; Stevens B; Thomas S; Walker R; Wynn R; Giugliani R; Harmatz P; Hendriksz C; Scarpa M; ;
    Orphanet J Rare Dis; 2019 May; 14(1):118. PubMed ID: 31142378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of oral manifestations of patients with mucopolysaccharidosis IV and VI: clinical and imaging study.
    de Almeida-Barros RQ; de Medeiros PFV; de Almeida Azevedo MQ; de Oliveira Lira Ortega A; Yamamoto ATA; Dornelas SKL; Bento PM
    Clin Oral Investig; 2018 Jan; 22(1):201-208. PubMed ID: 28315965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus-based expert recommendations on the management of MPS IVa and VI in Saudi Arabia.
    AlSayed M; Arafa D; Al-Khawajha H; Afqi M; Al-Sanna'a N; Sunbul R; Faden M
    Orphanet J Rare Dis; 2024 Jul; 19(1):269. PubMed ID: 39020431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease burden, management patterns and multidisciplinary clinical approaches for patients with MPS IVA and VI in selected Latin American Countries.
    Solano VM; Mandujano CYC; Avila-Rejon CA; Espin VH; Montaño HPQ
    Mol Genet Metab Rep; 2021 Sep; 28():100769. PubMed ID: 34113545
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glycosaminoglycans analysis in blood and urine of patients with mucopolysaccharidosis.
    Khan SA; Mason RW; Giugliani R; Orii K; Fukao T; Suzuki Y; Yamaguchi S; Kobayashi H; Orii T; Tomatsu S
    Mol Genet Metab; 2018 Sep; 125(1-2):44-52. PubMed ID: 29779903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multinational, multidisciplinary consensus for the diagnosis and management of spinal cord compression among patients with mucopolysaccharidosis VI.
    Solanki GA; Alden TD; Burton BK; Giugliani R; Horovitz DD; Jones SA; Lampe C; Martin KW; Ryan ME; Schaefer MK; Siddiqui A; White KK; Harmatz P
    Mol Genet Metab; 2012 Sep; 107(1-2):15-24. PubMed ID: 22938833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of sleep-disordered breathing and its relationship with respiratory parameters in children with mucopolysaccharidosis Type IVA and VI.
    Ademhan Tural D; Emiralioglu N; Dogru D; Ozsezen B; Ipek OF; Sunman B; Nayir Buyuksahin H; Guzelkas I; Ciki K; Kilic K; Vardar Yagli N; Yalcin E; Kiper N; Sivri S; Ozcelik U
    Am J Med Genet A; 2021 Aug; 185(8):2306-2314. PubMed ID: 33960649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries.
    Magner M; Almássy Z; Gucev Z; Kieć-Wilk B; Plaiasu V; Tylki-Szymańska A; Zafeiriou D; Zaganas I; Lampe C
    Orphanet J Rare Dis; 2022 May; 17(1):190. PubMed ID: 35538504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of pulmonary function impairments in patients with mucopolysaccharidoses--changes with age and treatment.
    Lin SP; Shih SC; Chuang CK; Lee KS; Chen MR; Niu DM; Chiu PC; Lin SJ; Lin HY
    Pediatr Pulmonol; 2014 Mar; 49(3):277-84. PubMed ID: 23401495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expensive drugs for rare disorders: to treat or not to treat? The case of enzyme replacement therapy for mucopolysaccharidosis VI.
    Schlander M; Beck M
    Curr Med Res Opin; 2009 May; 25(5):1285-93. PubMed ID: 19366306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate accumulation and extracellular matrix remodelling promote persistent upper airway disease in mucopolysaccharidosis patients on enzyme replacement therapy.
    Pal AR; Mercer J; Jones SA; Bruce IA; Bigger BW
    PLoS One; 2018; 13(9):e0203216. PubMed ID: 30226843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current diagnosis and management of mucopolysaccharidosis VI in the Asia-Pacific region.
    Hwu WL; Okuyama T; But WM; Estrada S; Gu X; Hui J; Kosuga M; Lin SP; Ngu LH; Shi H; Tanaka A; Thong MK; Wattanasirichaigoon D; Wasant P; McGill J
    Mol Genet Metab; 2012 Sep; 107(1-2):136-44. PubMed ID: 22864057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts].
    Giugliani R; Federhen A; Muñoz Rojas MV; Vieira TA; Artigalás O; Pinto LL; Azevedo AC; Acosta AX; Bomfim C; Lourenço CM; Kim CA; Horovitz D; Souza DB; Norato D; Marinho D; Palhares D; Santos ES; Ribeiro E; Valadares ER; Guarany F; De Lucca GR; Pimentel H; Souza IN; Corrêa Neto J; Fraga JC; Góes JE; Cabral JM; Simeonato J; Llerena JC; Jardim LB; Giuliani Lde R; Silva LC; Santos M; Moreira MA; Kerstenetzky M; Ribeiro M; Ruas N; Barrios P; Aranda P; Honjo R; Boy R; Costa R; Souza CF; Alcântara FF; Avilla SG; Fagondes S; Martins AM
    Rev Assoc Med Bras (1992); 2010; 56(3):271-7. PubMed ID: 20676532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice.
    Dvorak-Ewell M; Wendt D; Hague C; Christianson T; Koppaka V; Crippen D; Kakkis E; Vellard M
    PLoS One; 2010 Aug; 5(8):e12194. PubMed ID: 20808938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mucopolysaccharidosis type VI: case report with first neonatal presentation with ascites fetalis and rapidly progressive cardiac manifestation.
    Honjo RS; Vaca ECN; Leal GN; Abellan DM; Ikari NM; Jatene MB; Martins AM; Kim CA
    BMC Med Genet; 2020 Feb; 21(1):37. PubMed ID: 32075597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement.
    Stevens B; Kenny T; Thomas S; Morrison A; Jarrett J; Jain M
    Orphanet J Rare Dis; 2021 Sep; 16(1):394. PubMed ID: 34563214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.